As per NAVADHI Market Research, the global pharmaceutical industry [2] will we worth USD 1.57 trillion by 2023.
Johnson & Johnson and its subsidiaries (the Company) have approximately 134,000 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 260 operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases and Vaccines (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders and schizophrenia), Oncology (e.g., prostate cancer and hematologic malignancies), Cardiovascular and Metabolism (e.g., thrombosis and diabetes) and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension), a new therapeutic area, which was established with the acquisition of Actelion in June 2017. Ana finally The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and eye health fields.
Johnson & Johnson is the largest healthcare company by revenue which generated a whopping USD 81.58 billion in total sales in 2018, and pharmaceuticals franchise were responsible for more than 50% of the conglomerate's top line. In 2018, annual consumer care franchise rose just 1.8% and the medical device segment generated a marginal 1.5% gain. Quite evidently, Johnson & Johnson's pharmaceutical run the show and pushed total revenue to 7% higher last year.
The Company expected to generate sales of $80.4 billion to $81.2 billion reflecting expected operational growth in the range of 0.0% to 1.0% and expected adjusted operational growth in the range of 2.0% to 3.0%.
Spanning over 31 pages and 14 exhibits, “Johnson & Johnson - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Johnson & Johnson
*If Applicable.